Intrexon Corp (NYSE:XON) shares fell 5.9% during trading on Thursday . The stock traded as low as $14.82 and last traded at $15.11. 1,522,776 shares were traded during trading, a decline of 4% from the average session volume of 1,581,261 shares. The stock had previously closed at $16.05.

Several brokerages have recently commented on XON. ValuEngine raised shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, September 24th. JMP Securities raised their target price on shares of Intrexon from $42.00 to $43.00 and gave the stock a “market outperform” rating in a report on Wednesday. Zacks Investment Research cut shares of Intrexon from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Stifel Nicolaus began coverage on shares of Intrexon in a report on Tuesday, July 17th. They set a “buy” rating and a $72.00 target price on the stock. Finally, Bank of America cut shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 target price on the stock. in a report on Monday, July 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Intrexon currently has an average rating of “Hold” and an average price target of $29.67.

The firm has a market capitalization of $2.47 billion, a P/E ratio of -16.43 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.78.

Intrexon (NYSE:XON) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). The firm had revenue of $45.30 million during the quarter, compared to the consensus estimate of $51.70 million. Intrexon had a negative net margin of 82.17% and a negative return on equity of 16.67%. During the same period last year, the business earned ($0.16) earnings per share. On average, equities analysts predict that Intrexon Corp will post -0.79 EPS for the current fiscal year.

In related news, insider Helen Sabzevari sold 8,402 shares of Intrexon stock in a transaction that occurred on Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at $363,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 48.20% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Third Security LLC increased its stake in Intrexon by 0.3% in the second quarter. Third Security LLC now owns 59,309,806 shares of the biotechnology company’s stock valued at $826,779,000 after acquiring an additional 177,101 shares during the last quarter. BlackRock Inc. grew its stake in shares of Intrexon by 76.8% during the second quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock worth $64,788,000 after buying an additional 2,019,142 shares during the last quarter. Morgan Stanley grew its stake in shares of Intrexon by 6.7% during the second quarter. Morgan Stanley now owns 3,118,444 shares of the biotechnology company’s stock worth $43,470,000 after buying an additional 196,999 shares during the last quarter. Northern Trust Corp grew its stake in shares of Intrexon by 123.1% during the second quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock worth $12,791,000 after buying an additional 506,186 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Intrexon by 31.3% during the second quarter. Bank of America Corp DE now owns 738,264 shares of the biotechnology company’s stock worth $10,291,000 after buying an additional 176,105 shares during the last quarter. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Intrexon Company Profile (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: Leveraged Buyout (LBO)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.